Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
$4.05
+5.5%
$3.53
$1.96
$6.77
$12.08M0.7611,122 shs19,806 shs
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$2.16
$2.21
$1.62
$14.67
$5.12M0.98951,039 shs54,281 shs
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
$7.49
+0.4%
$6.62
$2.12
$12.55
$14.02M0.533,719 shs29,292 shs
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
$1.62
+2.5%
$1.48
$0.97
$19.44
$8.79M1.46451,546 shs82,785 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
+9.84%+4.25%+2.55%+28.41%+377,399,900.00%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
+2.37%-3.57%+0.47%+22.73%-69.45%
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
-1.32%0.00%+11.34%+45.14%+745,999,900.00%
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
+6.76%+1.94%-3.07%-20.20%+157,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
0.5891 of 5 stars
0.04.00.00.01.90.00.6
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
2.2354 of 5 stars
3.50.00.00.03.80.00.6
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
0.8174 of 5 stars
0.05.00.00.02.20.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
0.00
N/AN/AN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
0.00
N/AN/AN/A
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
3.00
Buy$21.00180.37% Upside
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
$9.59M1.33N/AN/A$3.49 per share1.16
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$5.21M0.98N/AN/A$2.59 per share0.83
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
$10K1,408.12N/AN/A$15.85 per share0.47
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
$230K39.16N/AN/A($8.66) per share-0.19
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
-$15.31M-$5.800.00N/A-194.50%-101.01%-43.90%8/12/2025 (Estimated)
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$7.99M-$6.54N/AN/AN/A-109.49%-192.54%-121.77%8/13/2025 (Estimated)
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
-$15.49MN/A0.00N/AN/AN/AN/AN/A9/29/2025 (Estimated)
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
-$166.52M-$32.810.00N/AN/A-15,245.81%N/A-193.21%8/21/2025 (Estimated)

Latest ENSC, NEUP, TRAW, and CSCI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$1.02N/AN/AN/A$0.67 millionN/A
5/20/2025Q3 2025
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
-$0.47$6.55+$7.02$6.55N/A$15.00 million
5/15/2025Q1 2025
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
-$8.04$2.09+$10.13$2.09$0.06 million$0.06 million
5/13/2025Q1 2025
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
N/A-$1.16N/A-$1.16N/A$1.50 million
5/13/2025Q1 2025
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$3.02-$1.39+$1.63-$1.39$0.65 million$1.32 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
N/AN/AN/AN/AN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/AN/AN/AN/AN/A
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
N/AN/AN/AN/AN/A
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
N/A
2.88
2.54
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/A
2.50
2.50
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
N/A
11.01
11.01
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
N/A
1.81
1.81

Institutional Ownership

CompanyInstitutional Ownership
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
0.73%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
5.63%
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
15.90%
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
7.95%

Insider Ownership

CompanyInsider Ownership
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
0.10%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
7.90%
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
0.69%
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
13.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
203.15 million3.14 millionN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
102.37 million2.18 millionNot Optionable
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
N/A1.88 million1.87 millionN/A
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
175.56 million4.81 millionOptionable

Recent News About These Companies

TRAW - Traws Pharma Inc Sustainability - Morningstar
Traws Pharma reports FY24 EPS ($35.21)
Traws Pharma Reports Full Year 2024 Results and Business Highlights

New MarketBeat Followers Over Time

Media Sentiment Over Time

COSCIENS Biopharma stock logo

COSCIENS Biopharma NASDAQ:CSCI

$4.05 +0.21 (+5.47%)
Closing price 03:59 PM Eastern
Extended Trading
$4.05 0.00 (0.00%)
As of 06:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

Ensysce Biosciences stock logo

Ensysce Biosciences NASDAQ:ENSC

$2.16 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$2.14 -0.02 (-0.93%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

Neuphoria Therapeutics stock logo

Neuphoria Therapeutics NASDAQ:NEUP

$7.49 +0.03 (+0.40%)
As of 03:42 PM Eastern

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Traws Pharma stock logo

Traws Pharma NASDAQ:TRAW

$1.62 +0.04 (+2.53%)
Closing price 04:00 PM Eastern
Extended Trading
$1.60 -0.02 (-0.93%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.